I hope this info is getting to the CDC as they are revising their Covid quarantine policy to cater to employers. Ironically, loosening the time frame will ultimately greatly diminish able workers.
In Dr. Michael Osterholm's most recent podcast, he cites a listener's experience in which a mother brought her Covid infected son to the ER (the infection had been confirmed). None of the medical personnel who treated him wore ANY type of mask, and they left the door open. The first place to start with prevention is in hospitals and clinics, but it seems even most doctors are no longer interested in this. Does the AMA have any position on this?
Will there be someone to replace Dr. Ashish Jha as the COVID czar and will they be at HHS? Can there be an international meeting at a site such as Cold Spring Harbor Laboratory (away from a political center) to stimulate translational medicine on Long COVID and related neuroinflammatory disorders?
Paul Friedrichs is the person who replaced Ashish Jha, working at the White House and HHS for pandemic management and preparedness. I don't know of any CSHL-like meeting but it's a good idea
Fascinating work in keeping with many studies to define LC in the context of persistence vs reinfection of the victims. The studies currently support the value of vaccination vs non-vaccination or incomplete vaccination in reducing the risk of getting LC but it still doesn’t answer the question about what to do with the increasing numbers of people who have let down their guard and plan to “take their chances” by declining vaccines. In the UK study of 2022 seeking clues from UK residents about risks of getting LC, a number of confounding variables were considered, and it is likely that Paxlovid was not available during that investigation. The questionnaire completed by the participants was an unbelievable array of both health and social issues (do read it in its entirety, about 5 pages but I can’t seem to copy the link without getting 5 pages so check it out). In our own medical questionnaire gathering HIPPA-approved information about acute COVID19 victims electing a propriety protocol with hydroxyurea (HU), we were able to garner over 600 case reports out of 2,500 prescriptions. Even the sickest victims had a prompt and complete resolution of their signs and symptoms. Those 450+ that graciously provided details had their case reports entered into the CURE ID CDRC website (devised by the FDA,CDC, NCATS, C-Path, I.D.S.A) whose purpose has/had been to get front-line information from real-world medical practitioners in order to define therapies with high-potential utilizing repurposed, safe drugs like hydroxyurea rather than some new un-tested molecule in the context of a pandemic scenario. HU has had a significant presence for several disorders for many decades with FDA approval. That UK survey might have shown some revealing outcomes and conclusions about LC if the COVID19 victim had taken Paxlovid (vs HU or other alternative Rx). As for our anecdotal 2,500 patients therapies and LC signs or symptoms, there were none nor were there any ADRs. In our collaborative experience with Biochemist/immunologists issues about acute COVID and LC are being defined with a broader view, namely the ultimate targets being disrupted by the immune response to the virus. In our conceptual framework, more mainstream concepts about residual viral elements or dormant virus is replaced with immune consequences from the anti-idiotypic antibodies to ubiquitous a7nAChRs, including those a7Rs associated with mitochondria.
Ref:
1. The role of α7 nicotinic acetylcholine receptors in post-acute sequelae of covid-19. Maryna Skok
I hope this info is getting to the CDC as they are revising their Covid quarantine policy to cater to employers. Ironically, loosening the time frame will ultimately greatly diminish able workers.
In Dr. Michael Osterholm's most recent podcast, he cites a listener's experience in which a mother brought her Covid infected son to the ER (the infection had been confirmed). None of the medical personnel who treated him wore ANY type of mask, and they left the door open. The first place to start with prevention is in hospitals and clinics, but it seems even most doctors are no longer interested in this. Does the AMA have any position on this?
Agree. They (doctors and the AMA) should!
Will there be someone to replace Dr. Ashish Jha as the COVID czar and will they be at HHS? Can there be an international meeting at a site such as Cold Spring Harbor Laboratory (away from a political center) to stimulate translational medicine on Long COVID and related neuroinflammatory disorders?
Paul Friedrichs is the person who replaced Ashish Jha, working at the White House and HHS for pandemic management and preparedness. I don't know of any CSHL-like meeting but it's a good idea
Fascinating work in keeping with many studies to define LC in the context of persistence vs reinfection of the victims. The studies currently support the value of vaccination vs non-vaccination or incomplete vaccination in reducing the risk of getting LC but it still doesn’t answer the question about what to do with the increasing numbers of people who have let down their guard and plan to “take their chances” by declining vaccines. In the UK study of 2022 seeking clues from UK residents about risks of getting LC, a number of confounding variables were considered, and it is likely that Paxlovid was not available during that investigation. The questionnaire completed by the participants was an unbelievable array of both health and social issues (do read it in its entirety, about 5 pages but I can’t seem to copy the link without getting 5 pages so check it out). In our own medical questionnaire gathering HIPPA-approved information about acute COVID19 victims electing a propriety protocol with hydroxyurea (HU), we were able to garner over 600 case reports out of 2,500 prescriptions. Even the sickest victims had a prompt and complete resolution of their signs and symptoms. Those 450+ that graciously provided details had their case reports entered into the CURE ID CDRC website (devised by the FDA,CDC, NCATS, C-Path, I.D.S.A) whose purpose has/had been to get front-line information from real-world medical practitioners in order to define therapies with high-potential utilizing repurposed, safe drugs like hydroxyurea rather than some new un-tested molecule in the context of a pandemic scenario. HU has had a significant presence for several disorders for many decades with FDA approval. That UK survey might have shown some revealing outcomes and conclusions about LC if the COVID19 victim had taken Paxlovid (vs HU or other alternative Rx). As for our anecdotal 2,500 patients therapies and LC signs or symptoms, there were none nor were there any ADRs. In our collaborative experience with Biochemist/immunologists issues about acute COVID and LC are being defined with a broader view, namely the ultimate targets being disrupted by the immune response to the virus. In our conceptual framework, more mainstream concepts about residual viral elements or dormant virus is replaced with immune consequences from the anti-idiotypic antibodies to ubiquitous a7nAChRs, including those a7Rs associated with mitochondria.
Ref:
1. The role of α7 nicotinic acetylcholine receptors in post-acute sequelae of covid-19. Maryna Skok
https://doi.org/10.1016/j.biocel.2024.106519
2. The Role of Hydroxyurea as an immunomodulator
https://pubmed.ncbi.nlm.nih.gov/34990284/